| INTRODUCTION
Spondyloarthritis (SpA) is a group of common chronic inflammatory rheumatic diseases, including ankylosing spondylitis (AS), psoriatic spondylitis (PsA), reactive arthritis, arthritis related to inflammatory bowel disease, and undifferentiated spondyloarthritis (uSpA). They are characterized mainly by affected axial skeleton, male predominance, and high tendency of familial aggregation. 1 Since its strong association with AS was reported in 1973, 2 the prevalence of human leukocyte antigen B*27 (HLA-B*27) and its role in the pathogenesis of SpA were extensively investigated in worldwide populations. 3 HLA-B*27 served as an important parameter for screening suspected SpA patients 4 and was also a predictor of poor prognosis. 5 Furthermore, in European descent, HLA-B*27 detection was recommended as the first and sole test for those suspected axial SpA.
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Of particular note, as the clinical arm, HLA-B*27 has been included in the new classification criteria for axial and peripheral SpA. 7 Aside from its assistance in clinical diagnosis, the role of HLA-B*27 in the pathogenesis of SpA has also been verified. Previous reports indicated that approximately 30% of the genetic susceptibility of SpA was ascribed to HLA-B*27, 8, 9 and the development of spondyloarthropathy-like disease in HLA-B*27 transgenic rats required high copies of B*27.
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Additionally, in a prior study, greater expression of HLA-B*27 was found in AS patients. 11 Furthermore, recent studies showed that non-B*27 susceptible genes might participate in the pathogenesis of SpA through interaction with HLA-B*27 or in an HLA-B*27-dependent manner. [12] [13] [14] These data, together with the finding that the subtypes of HLA-B*27 would influence the onset age of AS, 15 suggested that HLA-B*27 might not merely be a genetic marker but rather a related primary pathogenic factor.
Nowadays, it has been recognized that HLA-B*27 has numerous alleles. Of more importance, subtypes of HLA-B*27 showed varied distribution in different races and regions, and which also exhibited differences in genetic susceptibility to SpA. 16 A recent study described a set of primers to detect 42 HLA-B*27 alleles (B*2701-B*2721 and B*2723-B*2743). 17 However, with continued advances in genotyping, more and more HLA-B*27 subtypes have been identified. 18 In this context, subtyping of HLA-B*27 is need to be regularly updated to meet the requirements for investigating HLA-B*27 polymorphisms in the field of SpA.
Therefore, the present study aimed to establish an updated high- 
| MATERIALS AND METHODS

| Patients
Overall, 184 consecutive patients with SpA attending or followed by our department from January 2010 to January 2014 were enrolled in the present cross-sectional study. All of them belonged to Han nationality. All AS patients met the modified New York criteria, 19 and who were classified as juvenile ankylosing spondylitis (JAS) and adult ankylosing spondylitis (AAS) based on their onset age under or over 16 years. Patients including undifferentiated spondyloarthritis (uSpA) and psoriatic spondylitis (PsA) were classified according to the European Spondyloarthropathy Study Group (ESSG) criteria for SpA.
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The protocol was approved by the local ethics committee. All patients gave their written informed consents prior to enrollment in this study and their anonymity was preserved.
| Clinical data
Patients were interviewed via a standard questionnaire including de- Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)
were measured. Radiological sacroiliitis grading was undertaken randomly and blindly by two experienced rheumatologists according to the New York scoring method for sacroiliac joints. 22 If there was a discrepancy, the two specialists discussed and gave a conclusive grade or score.
| Typing and subtyping of HLA-B*27
Fasting peripheral venous blood were collected from all patients, and genomic DNA was extracted from whole blood samples using a standard salting-out method. On the basis of previously published studies, 17, [23] [24] [25] sequence specific primers for HLA-B*27 subtyping were updated in order to distinguish 56 subtypes of HLA-B*27
(B*2701-B*2721 and B*2723-B*2757). The corresponding specificities of primer pairs are listed in Table 1 . The primers amplifying a 796-bp fragment of HLA-DRB1 gene were applied to produce internal controls in the high-resolution HLA-B*27 subtyping. The universal negative and blank controls serving as quality controls were included in each amplification. The PCR product was analyzed by 2.5% agarose gel electrophoresis followed by ethidium bromide staining.
| Statistical analysis
Quantitative data were presented as means±SD and qualitative data were described with ratios or percentages. Quantitative data were analyzed with two independent samples using t test if the assumptions of homogeneity of variances and normality are met, otherwise the Wilcoxon rank sum test is used. With regard to qualitative data, the chi-square test, the continuity-adjusted chi-square, or Fisher's exact test when necessary was used. In order to control the effects of potential confounding variables, multivariate linear/
logistic regression were conducted to analyze the independent effects of HLA-B*27 status or subtypes, gender, age at onset, course of disease, and family history of SpA on acute phase reactants, radiographic sacroiliitis, disease pattern, and extra-articular features.
Odds ratios (OR) and regression coefficients (B) were calculated in logistic and linear regression models, respectively. A two-tailed P value <.05 was considered statistically significant. Statistical analyses were performed using SASv9.2.
| RESULTS
| HLA-B*27 typing and subtyping results
There were 162 AS (88.0%), 21 uSpA (11.4%), and 1 PsA patients T A B L E 1 Sequence and specificity of primers and PCR product sizes for high-resolution subtyping of HLA-B*27 No other significant differences were found between both groups as listed in Table 2 .
| Comparisons between different HLA-B*27 subtypes
In consideration of the potential effects of HLA-B*27 subtypes on the disease expression of SpA, comparisons of clinical manifestations were established among HLA-B*2704, B*2705, and B*2707 positive SpA patients. As presented in 
482-499(E3, R) TGATCTGAGCCGCCGTGC
The first two pairs of primers (G1 and G2) are used to HLA-B*27 typing, and the remaining pairs of primers are used to HLA-B*27subtyping. E2 means exon 2 and E3 means exon 3. F and R represent forward and reverse primers, respectively.
T A B L E 1 (Continued) Table 3, there were no significant differences observed between HLA-B*27 alleles with regard to the initial symptoms.
| DISCUSSION
HLA-B*27 is one of HLA class I molecule, which was broadly studied in different populations throughout the world due to its strong association with SpA. 3 It has been reported that HLA-B*27 was the most powerful parameter for distinguishing SpA from non-SpA patients in the ESSG classification criteria. 20 Moreover, it has also been suggested that the absence of HLA-B*27 is associated with a significant diagnostic delay. Yersinia or Salmonella infection. 26, 27 This finding combined with the inevitable cross reactivity of anti-HLA-B*27 antibodies compromised serological typing results of B*27 to some extent. 28 Another point that should be mentioned is that the number of HLA-B alleles is increasing continuously and therefore more and more subtypes of HLA-B*27 were found, and which showed different associations with SpA. 16 To solve this situation, polymerase Our present study established and tested an updated highresolution PCR-SSP typing set to accurately assign 56 alleles or subtypes of HLA-B*27 from B*2701 to B*2757 (B*2722 was deleted due to its sequence was identical to B*2706). Based on our results, the prevalence of HLA-B*27 was 94.0% in the total SpA patients, which was higher than that in ESPERANZA and emAR II studies, but similar to another investigation from China. [35] [36] [37] Furthermore, four subtypes of HLA-B*27 were detected in the total 184 SpA patients, namely, and B*2724 were also reported in Xinjiang Uygur AS patients.
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Collectively, these findings were consistent with several previously published studies.
17,40
Numerous studies have been conducted to investigate the crucial role of HLA-B*27 in susceptibility to SpA including AS. 8, 9, 16, 18 Indeed, relatively few studies performed the profound and prudent exploration of its effects on disease expression or clinical severity of SpA patients. 37, 39, 41 In the current study, a noticeably male predominance and markedly elevated CRP were found in B*27 positive SpA patients. In multivariable linear regression analysis, the elevated CRP was significantly associated with HLA-B*27 positivity, grade of sacroiliitis, and male gender. This result was in agreement with Liao et al., 42 but was contrary to the report from Chung et al. 43 The reasons for these discrepancies may not only be methodological, but may also reflect different treatment efficacy of nonsteroidal anti-inflammatory drugs, at least to some degree.
In order to investigate the subtle differences between HLA-B*27
subtypes, B*27 positive patients were stratified according to their HLA-B*27 alleles. Notably, there was also a sharply male predilection in B*2705 positive SpA patients. Contrary to those previous studies which reported that onset age of B*27 positive SpA patients was much younger than B*27 negative counterparts, 44,45 our study could not verify such an association between different groups. Similarly, a recent study did not find significant differences in onset age between B*2704 positive and B*27 negative Chinese JAS patients. 37 However, the present study found that a higher percentage of JAS was ob- SpA. 46 However, quite a few studies coming from different populations, in fact, have also reported B*2707 positive patients. 47, 48 Due to its relative rarity in our population, the right and eligible conclusion about this subtype need to be confirmed in a larger number of SpA patients.
In conclusion, our study developed a set of primers mixture for 
